Citius Pharmaceuticals, Inc. (CTXR): Price and Financial Metrics


Citius Pharmaceuticals, Inc. (CTXR): $2.01

0.03 (+1.52%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add CTXR to Watchlist
Sign Up

Industry: Biotech


Ranked

of 503

in industry

CTXR Stock Price Chart Interactive Chart >

Price chart for CTXR

CTXR Price/Volume Stats

Current price $2.01 52-week high $4.56
Prev. close $1.98 52-week low $0.87
Day low $1.97 Volume 1,768,900
Day high $2.05 Avg. volume 9,358,634
50-day MA $1.96 Dividend yield N/A
200-day MA $1.92 Market Cap 293.42M

Citius Pharmaceuticals, Inc. (CTXR) Company Bio


Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes critical care products. It primarily focuses on developing anti-infective, cancer care, prescription, and mesenchymal stem cell therapy products. The company is developing Mino-Lok, an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase III clinical trials; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.


CTXR Latest News Stream


Event/Time News Detail
Loading, please wait...

CTXR Latest Social Stream


Loading social stream, please wait...

View Full CTXR Social Stream

Latest CTXR News From Around the Web

Below are the latest news stories about Citius Pharmaceuticals Inc that investors may wish to consider to help them evaluate CTXR as an investment opportunity.

10 New Penny Stocks Redditors are Buying

In this article, we discuss the 10 new penny stocks Redditors are buying. If you want to skip our detailed analysis of these stocks, go directly to the 5 New Penny Stocks Redditors are Buying. Penny stocks have started gaining traction on popular Reddit forums in the past few months as retail investors, who are […]

Yahoo | September 16, 2021

Citius Pharmaceuticals to Join Benzinga All Access Show on Friday, September 17, 2021

Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on oncology, anti-infective products in adjunct cancer care, unique prescription products and stem cell therapies, today announced that it will be joining Benzinga's All Access Show for a 20-minute interview on Friday, September 17, 2021 at 10:10 am ET.

Yahoo | September 14, 2021

Why This Citius Analyst Thinks The Biopharma''s Shares Present 375% Upside Potential

Citius Pharmaceuticals, Inc. (NASDAQ: CTXR ) announced earlier this week an agreement…

Business Insider Markets | September 10, 2021

Citius (CTXR) Acquires Dr. Reddy's License for NHL Therapy

Citius Pharmaceuticals (CTXR) acquires Dr. Reddy's exclusive license rights for E7777 to treat a rare form of NHL and other cancer indications.

Yahoo | September 8, 2021

Citius Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15

Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on oncology, anti-infective products in adjunct cancer care, unique prescription products and stem cell therapies, today announced that it will present at the H.C. Wainwright 23rd Annual Global Investment Conference being held virtually September 13-15, 2021.

Yahoo | September 8, 2021

Read More 'CTXR' Stories Here

CTXR Price Returns

1-mo 5.24%
3-mo -48.98%
6-mo 5.79%
1-year 91.43%
3-year 13.56%
5-year -78.73%
YTD 97.06%
2020 0.00%
2019 -1.92%
2018 -72.63%
2017 -42.94%
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7944 seconds.